Randomized trial · people
Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes, an oral, once-daily form of amycretin lowered HbA1c more than placebo at all three doses tested, with gut side effects becoming more common at higher doses.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 186
- Published
- 2026
- Journal
- Lancet
What they tested
The team tested how different doses of once-daily oral amycretin (zenagamtide), a single molecule that acts on GLP-1, amylin and calcitonin receptors, change blood sugar control and safety compared with placebo in type 2 diabetes.
How the study was done
A randomized, double-blind, placebo-controlled, phase 2 dose-finding trial in 186 adults with type 2 diabetes already taking metformin, with or without an SGLT2 inhibitor, at 83 sites in 11 countries. Participants got 6, 25 or 50 mg of oral amycretin or a matching placebo (a dummy treatment) for 36 weeks, with doses stepped up from 1.5 mg every 4 weeks until each arm's target dose was reached.

What they found
HbA1c (a 3-month average of blood sugar) started at a mean of about 7.9% to 8.1%. By week 36 it fell by 0.9% in the 6 mg arm, 1.3% in the 25 mg arm and 1.4% in the 50 mg arm; compared with placebo, the differences were -0.5%, -0.99% and -1.09%, all statistically significant. Stomach and gut side effects were the most common, seen in 26% of the 6 mg arm, 41% of the 25 mg arm, 47% of the 50 mg arm and 23% of the placebo arm. Serious adverse events occurred in 7 participants, all taking amycretin (2, 2 and 3 across the dose arms), none on placebo, and nobody died.
What it doesn’t show
This was a mid-stage trial lasting 36 weeks with only 30 people on placebo, so it can't show longer-term effects or rarer side effects. It only included people with type 2 diabetes on metformin, and it was funded by Novo Nordisk.
The paper
Mora et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026.
The compound
More studies on Amycretin
- Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetesRandomized trial · people · 2026
- Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trialRandomized trial · people · 2025
- Amycretin: side effects all mild or moderate in first human trialRandomized trial · people · 2025
- Amycretin: similar drug exposure with kidney impairment in phase 1Clinical trial · people · 2026
- Amycretin cut body weight by 18% in obese rats over 21 daysAnimal study · mice and rats · 2025
- Every study on Amycretin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.